{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:10:59Z","timestamp":1768353059818,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T00:00:00Z","timestamp":1305590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10072-011-0618-0","type":"journal-article","created":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T06:07:42Z","timestamp":1305526062000},"page":"23-31","source":"Crossref","is-referenced-by-count":31,"title":["Memantine effects on behaviour in moderately severe to severe Alzheimer\u2019s disease: a post-marketing surveillance study"],"prefix":"10.1007","volume":"33","author":[{"name":"The Memantine Lombardy Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Clerici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Spila-Alegiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Pomati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Da Cas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Raschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,17]]},"reference":[{"key":"618_CR1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/WNL.46.1.130","volume":"46","author":"MS Mega","year":"1996","unstructured":"Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in Alzheimer\u2019s disease. Neurology 46:130\u2013135","journal-title":"Neurology"},{"key":"618_CR2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","volume":"157","author":"CG Lyketsos","year":"2000","unstructured":"Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on memory in aging. Am J Psychiatry 157:708\u2013714","journal-title":"Am J Psychiatry"},{"key":"618_CR3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1212\/WNL.37.10.1649","volume":"37","author":"Y Stern","year":"1987","unstructured":"Stern Y, Mayeux R, Sano M, Hauser WA, Bush T (1987) Predictors of disease course in patients with probable Alzheimer\u2019s disease. Neurology 37:1649\u20131653","journal-title":"Neurology"},{"key":"618_CR4","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1001\/jama.287.16.2090","volume":"287","author":"K Yaffe","year":"2002","unstructured":"Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, Covinsky KE (2002) Patient and caregiver characteristics and nursing home placement in patients with dementia. Jama 287:2090\u20132097","journal-title":"Jama"},{"key":"618_CR5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000074281","volume":"17","author":"ZJ Wynn","year":"2004","unstructured":"Wynn ZJ, Cummings JL (2004) Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 17:100\u2013108","journal-title":"Dement Geriatr Cogn Disord"},{"key":"618_CR6","doi-asserted-by":"crossref","unstructured":"Lonergan E, Luxenberg J, Colford J (2002) Haloperidol for agitation in dementia. Cochrane Database Syst Rev:CD002852","DOI":"10.1002\/14651858.CD002852"},{"key":"618_CR7","unstructured":"Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease. Cochrane Database Syst Rev:CD003476"},{"key":"618_CR8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","volume":"5","author":"SA Lipton","year":"2006","unstructured":"Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160\u2013170","journal-title":"Nat Rev Drug Discov"},{"key":"618_CR9","unstructured":"Committee for proprietary medicinal products (2002) Meeting of 19 to 21 February 2002 [press release; EMEA\/CPMP\/561\/02] EMEA, London"},{"key":"618_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"key":"618_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.1996.tb00261.x","volume":"3","author":"E Magni","year":"1996","unstructured":"Magni E, Binetti G, Bianchetti A, Rozzini R, Trabucchi M (1996) Mini-mental state examination: a normative study in Italian elderly population. Eur J Neurol 3:1\u20135","journal-title":"Eur J Neurol"},{"key":"618_CR12","unstructured":"NICE NIfHaCE (2007) Alzheimer\u2019s disease\u2014donepezil, galantamine, rivastigmine (review) and memantine. Technology Appraisal Guidance 111: http:\/\/guidance.nice.org.uk\/TA111"},{"key":"618_CR13","unstructured":"Committee for medicinal products for human use (2005) Postauthorization summary of opinion for Ebixa [EMEA\/CHMP\/341433\/2005] EMEA, London"},{"key":"618_CR14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"618_CR15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","volume":"24","author":"B Winblad","year":"2007","unstructured":"Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ (2007) Memantine in moderate to severe Alzheimer\u2019s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 24:20\u201327","journal-title":"Dement Geriatr Cogn Disord"},{"key":"618_CR16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1345\/aph.1K372","volume":"42","author":"ID Maidment","year":"2008","unstructured":"Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL (2008) Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 42:32\u201338","journal-title":"Ann Pharmacother"},{"key":"618_CR17","doi-asserted-by":"crossref","unstructured":"McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev:CD003154","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"618_CR18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","volume":"20","author":"S Gauthier","year":"2005","unstructured":"Gauthier S, Wirth Y, Mobius HJ (2005) Effects of memantine on behavioural symptoms in Alzheimer\u2019s disease patients: an analysis of the neuropsychiatric inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 20:459\u2013464","journal-title":"Int J Geriatr Psychiatry"},{"key":"618_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/01.wnl.0000223333.42368.f1","volume":"67","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, Schneider E, Tariot PN, Graham SM (2006) Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67:57\u201363","journal-title":"Neurology"},{"key":"618_CR20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","volume":"69","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Ballard CG, Cooper JA, Loft H (2008) Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer\u2019s disease: a pooled analysis of 3 studies. J Clin Psychiatry 69:341\u2013348","journal-title":"J Clin Psychiatry"},{"key":"618_CR21","unstructured":"Regione Lombardia (2005) Progetto di monitoraggio della somministrazione di memantina a pazienti con malattia di Alzheimer (AD). D.G.R.: VII\/20954"},{"key":"618_CR22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002512-200926040-00003","volume":"26","author":"F Clerici","year":"2009","unstructured":"Clerici F, Vanacore N, Elia A, Spila-Alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C (2009) Memantine in moderately severe-to-severe Alzheimer\u2019s disease: a postmarketing surveillance study. Drugs Aging 26:321\u2013332","journal-title":"Drugs Aging"},{"key":"618_CR23","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of Illness in the Aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA 185:914\u2013919","journal-title":"JAMA"},{"key":"618_CR24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archneur.55.4.539","volume":"55","author":"G Binetti","year":"1998","unstructured":"Binetti G, Mega MS, Magni E, Padovani A, Rozzini L, Bianchetti A, Trabucchi M, Cummings JL (1998) Behavioral disorders in Alzheimer disease: a transcultural perspective. Arch Neurol 55:539\u2013544","journal-title":"Arch Neurol"},{"key":"618_CR25","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308\u20132314","journal-title":"Neurology"},{"key":"618_CR26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","volume":"43","author":"PA Parmelee","year":"1995","unstructured":"Parmelee PA, Thuras PD, Katz IR, Lawton MP (1995) Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 43:130\u2013137","journal-title":"J Am Geriatr Soc"},{"key":"618_CR27","volume-title":"ECDEU assessment manual for psychopharmachology","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmachology. National Institute of Mental Health, Rockville"},{"key":"618_CR28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/gps.1203","volume":"19","author":"A Mirakhur","year":"2004","unstructured":"Mirakhur A, Craig D, Hart DJ, McLlroy SP, Passmore AP (2004) Behavioural and psychological syndromes in Alzheimer\u2019s disease. Int J Geriatr Psychiatry 19:1035\u20131039","journal-title":"Int J Geriatr Psychiatry"},{"key":"618_CR29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMp058174","volume":"353","author":"J Avorn","year":"2005","unstructured":"Avorn J (2005) FDA standards\u2014good enough for government work? N Engl J Med 353:969\u2013972","journal-title":"N Engl J Med"},{"key":"618_CR30","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med 348:1333\u20131341","journal-title":"N Engl J Med"},{"key":"618_CR31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1532-5415.1997.tb02960.x","volume":"45","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Olin JT, Lyness SA, Chui HC (1997) Eligibility of Alzheimer\u2019s disease clinic patients for clinical trials. J Am Geriatr Soc 45:923\u2013928","journal-title":"J Am Geriatr Soc"},{"key":"618_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"P Raina","year":"2008","unstructured":"Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379\u2013397","journal-title":"Ann Intern Med"},{"key":"618_CR33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/01.JGP.0000221293.91312.d3","volume":"14","author":"JL Cummings","year":"2006","unstructured":"Cummings JL, McRae T, Zhang R (2006) Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14:605\u2013612","journal-title":"Am J Geriatr Psychiatry"},{"key":"618_CR34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","volume":"23","author":"S Gauthier","year":"2008","unstructured":"Gauthier S, Loft H, Cummings J (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer\u2019s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 23:537\u2013545","journal-title":"Int J Geriatr Psychiatry"},{"key":"618_CR35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/WAD.0b013e318065c495","volume":"21","author":"CH Dyck van","year":"2007","unstructured":"van Dyck CH, Tariot PN, Meyers B, Malca Resnick E (2007) A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 21:136\u2013143","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"618_CR36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0002-9343(90)90182-D","volume":"89","author":"RI Horwitz","year":"1990","unstructured":"Horwitz RI, Viscoli CM, Clemens JD, Sadock RT (1990) Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 89:630\u2013638","journal-title":"Am J Med"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-011-0618-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-011-0618-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-011-0618-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T16:18:20Z","timestamp":1560183500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-011-0618-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s10072-011-0618-0","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,17]]}}}